Analyst upgrades typically lead to a positive short-term reaction in a stock's price as they suggest a better-than-previously-expected future performance of the company. The upgrade from Neutral to Outperform by a reputable analyst like Andreas Argyrides can be seen as a strong endorsement of Unity Biotechnology's prospects, potentially leading to increased investor confidence and a rise in stock price.